PARP1/2 inhibitors (PARPis) are the first class of drugs acting by the principle of synthetic lethality that have been approved for clinical use for the treatment of homologous recombination (HR)-deficient types of cancer (mainly, BRCA1/2-deficient ovarian and breast cancers) [26]. This evidence concerns the gene BRCA1 and breast cancer.